BACKGROUND: Iron metabolism is essential because it plays regulatory roles in various physiological and pathological processes. Disorders of iron metabolism balance are related to various cancers, including hepatocellular carcinoma. Cancer stem-like cells (CSCs) exert critical effects on chemotherapy failure, cancer metastasis, and subsequent disease recurrence and relapse. However, little is known about how iron metabolism affects liver CSCs. Here, we investigated the expression of transferrin receptor 1 (TFR1) and ferroportin (FPN), two iron importers, and an upstream regulator, iron regulatory protein 2 (IRP2), in liver hepatocellular carcinoma (LIHC) and related CSCs. METHODS: The expression levels of TFR1, FPN and IRP2 were analysed using the GEPIA database. CSCs were derived from parental LIHC cells cultured in serum-free medium. After TFR1 knockdown, ROS accumulation and malignant behaviours were measured. The CCK-8 assay was performed to detect cell viability after TFR1 knockdown and erastin treatment. RESULTS: TFR1 expression was upregulated in LIHC tissue and CSCs derived from LIHC cell lines, prompting us to investigate the roles of TFR1 in regulating CSCs. Knockdown of TFR1 expression decreased iron accumulation and inhibited malignant behaviour. Knockdown of TFR1 expression decreased reactive oxygen species (ROS) accumulation induced by erastin treatment and maintained mitochondrial function, indicating that TFR1 is critical in regulating erastin-induced cell death in CSCs. Additionally, knockdown of TFR1 expression decreased sphere formation by decreasing iron accumulation in CSCs, indicating a potential role for TFR1 in maintaining stemness. CONCLUSION: These findings, which revealed TFR1 as a critical regulator of LIHC CSCs in malignant behaviour and stemness that functions by regulating iron accumulation, may have implications to improve therapeutic approaches.
BACKGROUND:Iron metabolism is essential because it plays regulatory roles in various physiological and pathological processes. Disorders of iron metabolism balance are related to various cancers, including hepatocellular carcinoma. Cancer stem-like cells (CSCs) exert critical effects on chemotherapy failure, cancer metastasis, and subsequent disease recurrence and relapse. However, little is known about how iron metabolism affects liver CSCs. Here, we investigated the expression of transferrin receptor 1 (TFR1) and ferroportin (FPN), two iron importers, and an upstream regulator, iron regulatory protein 2 (IRP2), in liver hepatocellular carcinoma (LIHC) and related CSCs. METHODS: The expression levels of TFR1, FPN and IRP2 were analysed using the GEPIA database. CSCs were derived from parental LIHC cells cultured in serum-free medium. After TFR1 knockdown, ROS accumulation and malignant behaviours were measured. The CCK-8 assay was performed to detect cell viability after TFR1 knockdown and erastin treatment. RESULTS:TFR1 expression was upregulated in LIHC tissue and CSCs derived from LIHC cell lines, prompting us to investigate the roles of TFR1 in regulating CSCs. Knockdown of TFR1 expression decreased iron accumulation and inhibited malignant behaviour. Knockdown of TFR1 expression decreased reactive oxygen species (ROS) accumulation induced by erastin treatment and maintained mitochondrial function, indicating that TFR1 is critical in regulating erastin-induced cell death in CSCs. Additionally, knockdown of TFR1 expression decreased sphere formation by decreasing iron accumulation in CSCs, indicating a potential role for TFR1 in maintaining stemness. CONCLUSION: These findings, which revealed TFR1 as a critical regulator of LIHC CSCs in malignant behaviour and stemness that functions by regulating iron accumulation, may have implications to improve therapeutic approaches.
Authors: Matthew F Buas; Jung-hyun Rho; Xiaoyu Chai; Yuzheng Zhang; Paul D Lampe; Christopher I Li Journal: Breast Cancer Res Treat Date: 2015-08-30 Impact factor: 4.872
Authors: Lia Tesfay; Kathryn A Clausen; Jin Woo Kim; Poornima Hegde; Xiaohong Wang; Lance D Miller; Zhiyong Deng; Nicole Blanchette; Tara Arvedson; Cindy K Miranti; Jodie L Babitt; Herbert Y Lin; Donna M Peehl; Frank M Torti; Suzy V Torti Journal: Cancer Res Date: 2015-04-09 Impact factor: 12.701
Authors: Zandra K Pinnix; Lance D Miller; Wei Wang; Ralph D'Agostino; Tim Kute; Mark C Willingham; Heather Hatcher; Lia Tesfay; Guangchao Sui; Xiumin Di; Suzy V Torti; Frank M Torti Journal: Sci Transl Med Date: 2010-08-04 Impact factor: 17.956
Authors: E R Camp; C Wang; E C Little; P M Watson; K F Pirollo; A Rait; D J Cole; E H Chang; D K Watson Journal: Cancer Gene Ther Date: 2013-03-08 Impact factor: 5.987
Authors: Nadia Lobello; Flavia Biamonte; Maria Elena Pisanu; Maria Concetta Faniello; Žiga Jakopin; Emanuela Chiarella; Emilia Dora Giovannone; Rita Mancini; Gennaro Ciliberto; Giovanni Cuda; Francesco Costanzo Journal: Oncotarget Date: 2016-09-20